Dyadic Q2 2026 revenue flat at $961K; net loss $2.12M, cash down to $4.79M

DYADIC INTERNATIONAL INC

2026-Q2 EPS reported -$0.11 revenue$2,072,094

Revenue $961,138, down 0.6% YoY; grant revenue up $334K, R&D revenue down $89.6K.
Net loss $2,123,884 ($0.06/share) vs $1,793,774 ($0.06/share) a year ago.
Cash and investments $4.79M at June 30, down from $8.59M at Dec 31, 2025.
Commercial progress: shipments of 6 recombinant proteins, pilot sales for cultivated meat, IBT Bioservices OEM shipments, Proliant Albufree DX launch.
Transferrin productivity up ~80% at pilot scale; Gates Foundation RSV/malaria mAb programs advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.